Drug Profile
TPI
Alternative Names: Thymidine phosphorylase inhibitorLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Developer Kagoshima University; Taiho Pharmaceutical
- Class
- Mechanism of Action Thymidine phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer metastases
Most Recent Events
- 03 Apr 2003 No development reported - Preclinical for Cancer metastases in Japan (unspecified route)
- 04 Dec 2000 Preclinical development for Cancer metastases in Japan (Unknown route)